The Ministry of Food and Drug Safety announced that it has started review for the Emergency Use Authorization of US Merck’s oral COVID-19 treatment, ‘Lagebvrio (molnupiravir).’ Also, the ministry added that a preliminary review is also in progress for US Pfizer’s ‘Paxlovid.’

On the 17th, the Korea Disease Control and Prevention Agency requested an emergency use authorization for US Merck’s oral COVID-19 treatment ‘Lagebvrio’ to the MFDS.

Lagebvrio is a ribonucleoside analog that is inserted in place of the normal RNA needed in the viral replication process to induce lethal mutagenesis.

The MFDS plans to carefully review the clinical and quality data submitted by t